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Introduction
Important advances in the field of heart transplantation
have been accomplished during the last two decades. As
a result, current survival rates are 85% and 70% after
1 and 5 years, respectively. The most conspicuous
improvement in survival was associated with the intro-
duction of cyclosporine treatment in the 1980s, which
reduced mortality from infectious complications.
Despite these advances, rejection and infection remain
the leading causes of mortality during the first year after
transplantation. In contrast, accelerated coronary artery
disease has emerged as the major determinant of long-
term survival. The clinical importance of graft athero-
sclerosis is attested to by the fact that up to 50%
of cardiac transplant recipients have angiographically
detectable coronary artery lesions 5 years after trans-
plantation'11, and 50% of these will develop graft failure.
Virtually all patients who survive beyond the 5th year
after transplantation have histopathological evidence of
coronary artery disease'21.
Graft atherosclerosis is characterized by diffuse
intimal thickening that results in an accelerated narrow-
ing of the coronary vessels. Intimal thickening is detect-
able by intracoronary ultrasound in a substantial
proportion of transplant recipients with no angiographic
abnormalities'31. This discrepancy between ultrasono-
graphic and angiographic findings may be due to the
diffuse pattern of intimal thickening in graft athero-
sclerosis and the compensatory enlargement of the
affected vessels'41.
The underlying mechanisms of graft atheroscler-
osis have not yet been fully elucidated, but, immunologi-
cal mechanisms certainly play a crucial role'561. This is
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already suggested by the simple observation that, while
transplanted vessels develop atherosclerotic changes, the
host's native arteries are spared. Graft endothelium is
the primary target of the immunological responses to the
allograft due to the expression of alloantigens on its
surface, which activate host helper T cells'51. Immune-
mediated endothelial injury causes endothelial dysfunc-
tion with abnormal vasodilation. The present paper
reviews recent reports that have shed new light on the
pathogenesis and clinical significance of endothelial dys-
function as an early manifestation of graft vasculopathy.
Clinical evidence of graft endothelial
dysfunction
Intact endothelium releases a number of mediators that
regulate vascular tone and growth in response to
changes in shear stress and other haemodynamic and
metabolic factors'7'. One important endothelial product
is nitric oxide, which is formed from L-arginine by the
enzyme nitric oxide synthase. Damage to the endo-
thelium may result in reduced production and/or nitric
oxide and other vasoactive substances such as prosta-
cyclines. Functional endothelial disturbances are clini-
cally detectable as abnormal vasomotor responses to
endothelium-dependent vasodilators such as acetyl-
choline or substance P. Reduced coronary vasodilation,
or vasoconstruction, in response to these agents has
been observed in a substantial proportion of cardiac
transplant recipients'8"151. In contrast, endothelium-
independent vasodilators such as nitroglycerine,
papaverine, and adenosine usually elicit normal vasodi-
lator responses'13"171.
A bicycle exercise test can be used instead of
pharmacological agents to assess the endothelium-
dependent vasomotor response of the coronary
arteries'17'. Exercise-induced coronary vasodilation was
reversibly lost after endothelial denudation in an exper-
imental study'181. Both epicardial coronary vasodilation
and coronary flow reserve during exercise were normal
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2-3 months after transplantation, but decreased 1-5
years later in heart transplant recipients'17'. Coronary
blood flow measurements with positron-emission tom-
ography confirmed that exercise-dependent flow reserve
is reduced in transplant recipients, possibly due to
increased blood flow at rest rather than to an abnormal
increase of flow during exercise.'191. Abnormal
acetylcholine-induced coronary vasodilation was
improved by administration of L-arginine in transplant
recipients, suggesting that endothelial dysfunction may
initially be reversible'121. The responses of the endo-
thelium to different stimuli may become impaired at
different time points after transplantation: the vaso-
motor response to acetylcholine'811' and to the cold-
pressor test'201 may be abnormal a few weeks to months
after transplantation, whereas exercise-induced vaso-
dilation is typically maintained for several months or
even a few years'17'. Similar vasomotor abnormalities
have been shown in non-transplant patients with
coronary artery disease'21'.
Pathogenesis of graft endothelial
dysfunction and atherosclerosis
The 'response to injury' hypothesis, first formulated by
Ross'22' as an explanation for atherogenesis in non-
transplant patients, also provides a conceptual frame-
work for understanding graft vasculopathy'23'24'.
According to this model, a number of factors, including
allograft rejection, peri-operative hypoxia, viral infec-
tions, cyclosporine toxicity, and traditional cardio-
vascular risk factors, may cause endothelial injury. In
response to the variety of perturbing agents, the
endothelium displays a quite uniform pattern of reac-
tion. Activated host helper T cells release interleukin-2
that leads to the proliferation of other alloreactive cells,
which secrete additional cytokines onto the intimal
surface. In response, the endothelium expresses cell
surface antigens and adhesion molecules and secretes
macrophage chemoattractant factor. Recruited macro-
phages and activated lymphocytes enter the vessel wall
and release cytokines and mitogenic factors such as
interleukin-1, fibroblast growth factor, platelet-derived
growth factors, transforming growth factor-a (TGF-a)
and tumour necrosis factor-a (TNF-a)'25'27'. Cytokines,
in turn, enhance macrophage and vascular smooth
muscle cell migration and proliferation as well as extra-
cellular matrix deposition. A role for TNF-a and vascu-
lar cell adhesion molecules'28"30' in the pathogenesis of
graft vasculopathy is supported by the observation that
blockade of TNF-a prevents graft coronary athero-
sclerosis in cholesterol-fed rabbits, while anti-adhesion
molecules have similar effects in transplanted mice.'31'.
Furthermore, increased circulating levels of intercellular
adhesion molecule-1 (ICAM-1) are associated with
reduced survival in transplanted patients'32'.
The participation of specific immune mediators
and inflammatory cell types in the genesis of graft
vasculopathy was examined in a recent study in which
carotid arteries were transplanted between pairs of
inbred mice in both syngeneic and allogeneic combina-
tions'33'34'. Seven mutant strains of mice, each with a
specific immunological defect, were used for these exper-
iments. While an acquired immune response involving
CD4+ (helper) T cells, antibody, and macrophages was
essential to concentric neointimal proliferation and
luminal narrowing, CD8+ (cytotoxic) T cells and natural
killer cells were not involved in this process.
Experimental data suggest a link between acute
cellular rejection and graft vasculopathy'35', but clinical
data are controversial in this regard'3637'. However, the
vascular (or humoral) pattern of allograft rejection,
which lacks large myocardial inflammatory infiltrates on
histologic examination, is clearly associated with an
increased risk of subsequent graft atherosclerosis'38'39'.
Antibodies against a doubling of endothelial antigens
(molecular mass 60 and 62 kDa) have been detected
in the serum of patients in whom accelerated athero-
sclerosis developed during the first 2 years after trans-
plantation'40'. Lower levels of the antibodies were also
found in a minority of patients in whom graft vasculopa-
thy developed after the second year after transplantation
and in rare cases of non-transplant patients with cor-
onary artery disease. It is not clear whether such anti-
bodies are primarily responsible for endothelial injury or
whether they are secondarily produced as a result of
prior damage to the endothelium.
Cyclosporine treatment may cause endothelial
dysfunction with decreased prostacyclin production'41"43',
resulting in arterial vasoconstriction that is synergisti-
cally potentiated by angiotensin II'44'. Cyclosporine also
upregulates the expression of major histocompatibility
complex antigens'45'46' and vascular adhesion mol-
ecules'47', while inducing vascular inflammatory cell
infiltrates'46'48' and smooth muscle cell proliferation'49'.
Allograft rejection in cyclosporine-treated animals is
characterized by a vascular rather than myocardial
inflammatory pattern'46', which is associated with accel-
erated graft arteriosclerosis'50'. In contrast to these
experimental data, the analysis of large cohorts of heart
transplant recipients showed that the incidence of
graft atherosclerosis has remained substantially
unchanged after the introduction of cyclosporine-based
immunosuppression'51"53'. Cyclosporine dose reduction,
started 1 year after heart transplantation, had no
beneficial effect on coronary artery narrowing compared
with the conventional dosage in a prospective study'54'.
Cytomegalovirus infection, the most frequent
infectious complication in transplanted patients,
can induce vascular inflammation and graft
atherosclerosis'55""57'. Experimental data suggest a
protective effect of ganciclovir prophylaxis against graft
vasculopathy'58'.
Finally, conventional vascular risk factors such
as hyperlipidaemia and hypertension also induce
endothelial dysfunction and may enhance graft athero-
sclerosis'59'60'. High plasma LDL cholesterol levels and
the presence of multiple vascular risk factors were
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associated with impaired coronary artery vasodilation
during exercise in transplant recipients'6'1.
In summary, the pathogenesis of graft endo-
thelial dysfunction and atherosclerosis is multifactorial:
immune-mediated mechanisms are probably crucial in
initiating endothelial injury, while cyclosporine treat-
ment, cytomegalovirus infection, and vascular risk fac-
tors may contribute to the progression of the disease.
Prognostic implications of endothelial
dysfunction
Discordant findings have been reported on the predictive
value of endothelial dysfunction for later development
of graft atherosclerosis. Angiographic studies have
shown that acetylcholine-induced coronary vasodilation
2 months after transplantation may be impaired to the
same extent in patients with and without angiographic
evidence of graft vasculopathy at 1-year follow-up'621.
An intravascular ultrasound study showed impaired
vasodilation in 13 of 22 normal coronary segments 1
year after transplantation, whereas it was maintained in
9 of 11 segments with intimal thickening 5 years after
transplantation'631. A recent study using serial intra-
vascular ultrasound showed that coronary segments
with endothelial dysfunction had a greater increase in
intimal thickness than normally dilating segments 1 year
after transplantation'64'. These data suggest that
endothelial dysfunction is an early, potentially reversible
manifestation of graft vasculopathy and that it has a
moderate predictive value for the subsequent develop-
ment of arterial lesions. Intimal thickening, which rep-
resents a more advanced stage of the disease, has
stronger prognostic implications than vasomotor abnor-
malities'651. For this reason, serial intracoronary ultra-
sound imaging has become the gold standard for the
monitoring of the progression of graft vasculopathy'661.
Potential therapeutic approaches to
graft vasculopathy
The prevention of graft vasculopathy is one of
the major challenges facing cardiovascular research
today. Potential therapeutic approaches include
new immunosuppressive agents, corticosteroid-free
regimens, cytomegalovirus prophylaxis, and the use of
vasodilators and lipid-lowering drugs.
Rapamycin, an inhibitor of T-cell proliferation,
was associated with a protective effect against graft
atherosclerosis in a recent clinical trial'671. Elafin, an
inhibitor of elastolytic activity (which is increased in
graft vasculopathy), and monoclonal antibodies against
vascular adhesion molecules also inhibited graft vascu-
lopathy in experimental models'31'681. Despite these
promising results, none of the new immunosuppressive
agents has clearly improved on cyclosporine treatment.
Cyclosporine-based, corticosteroid-free immunosup-
pression is associated with a reduced atherogenetic risk
and is feasible in a majority of transplant recipients'691.
Cyclosporine monotherapy with suppression of steroid
and azathioprine treatment within 12 and 18 months
respectively, after transplantation reduced the incidence
of infectious complications with no increased risk of
rejection'701.
Although ganciclovir prophylaxis prevented
graft atherosclerosis in an experimental model'581 and
reduced the overall incidence of cytomegalovirus
disease in transplanted patients, it failed to protect
cytomegalovirus-seronegative patients receiving hearts
from seropositive donors'7'1. The best prophylactic effect
might be achieved with a combination of ganciclovir and
cytomegalovirus hyperimmune globulin, which reduces
the incidence of acute rejection through independent
humoral mechanisms'721. The effect of gancyclovir
prophylaxis on the development of graft atherosclerosis
still needs to be examined in a prospective clinical trial.
Another experimental approach to the treatment
of graft vasculopathy has focused on nitric oxide, an
endogenous vasodilator that also inhibits vascular
smooth muscle cell proliferation'731 and T-cell acti-
vation'741. Administration of L-arginine, the precursor of
nitric oxide, inhibited the development of atherosclerosis
in hypercholesterolaemic rabbits'751. Intracoronary in-
fusion of L-arginine to cardiac transplant recipients
normalized the vasomotor response to acetylcholine in a
majority of patients'171. However, oral administration of
L-arginine failed to prevent myointimal proliferation,
although it enhanced vascular nitric oxide production, in
an animal model of alloimmune injury'761.
Diltiazem, a calcium channel blocker, has
recently attracted attention as a possible treatment for
graft vasculopathy. Calcium channel blockers reduced
the progression of atherosclerotic lesions in cholesterol-
fed animals'771 and in humans with native coronary
artery disease'78'791. Treatment with diltiazem reduced
coronary artery narrowing and decreased both mortality
from graft atherosclerosis and overall mortality in the
first year after transplantation'801. Another calcium
antagonist, amlodipine, and angiotensin-coverting
enzyme inhibitors had a protective effect against graft
vasculopathy in experimental models'81'821. The mecha-
nisms that are responsible for these effects are not fully
understood. Suppression of calcium-dependent smooth
muscle cell migration and proliferation and/or chronic
vasodilation with an increase in coronary blood flow
and, thus, flow-dependent production of nitric oxide by
the endothelium have been postulated'831. However,
other studies have questioned the efficacy of diltiazem
in preventing graft vasculopathy because differences
in coronary artery diameter appeared to be due to
acute vasodilation rather than to structural vascular
changes'84'851.
A new potential approach to the treatment of
graft vasculopathy is the administration of pravastatin,
a 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitor, which prevented coronary artery narrowing in a
recent prospective study'86'. Surprisingly, the protective
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effect of pravastatin was independent of its lipid-
lowering effect and was associated with a decreased
incidence of haemodynamically relevant rejection and
improved 1-year survival after transplantation. These
findings were explained with a pravastatin-induced
decrease in the cytotoxicity of natural killer-cells.
Based on these observations, treatment with
diltiazem and pravastatin may be considered in trans-
plant recipients with ultrasonographic or angiographic
evidence of coronary artery disease. Prophylactic
administration of these agents in the first year after
transplantation is also being debated due to their ben-
eficial effect on short-term survival180861. However, the
efficacy of diltiazem and pravastatin in preventing graft
atherosclerosis needs to be confirmed in additional pro-
spective trials before these treatments are universally
accepted.
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